MYMD - MyMD Pharmaceuticals, Inc. Stock Price, Fair Value and News

2.98USD+0.08 (+2.76%)Delayed as of 30 Apr 2024, 12:24 pm ET

Market Summary

USD2.98+0.08

Delayedas of 30 Apr 2024, 12:24 pm

2.76%

MYMD Stock Price

View Fullscreen

MYMD RSI Chart

MYMD Valuation

Market Cap

6.3M

Price/Earnings (Trailing)

-1.56

Price/Sales (Trailing)

3.12

EV/EBITDA

-0.89

Price/Free Cashflow

-0.48

MYMD Price/Sales (Trailing)

MYMD Profitability

EBT Margin

-253.64%

Return on Equity

-32.34%

Return on Assets

-22.39%

Free Cashflow Yield

-207.45%

MYMD Fundamentals

MYMD Revenue

Revenue (TTM)

1.6M

MYMD Earnings

Earnings (TTM)

-4.0M

Earnings Growth (Yr)

36.9%

Earnings Growth (Qtr)

-158.46%

Breaking Down MYMD Revenue

52 Week Range

2.98

(Low)(High)

Last 7 days

12.4%

Last 30 days

21.3%

Last 90 days

-41.1%

Trailing 12 Months

-94.7%

How does MYMD drawdown profile look like?

MYMD Financial Health

Current Ratio

1.17

MYMD Investor Care

Shares Dilution (1Y)

64.00%

Diluted EPS (TTM)

-6.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	0	0	0	0
2020	0	0	0	0
2019	2.0M	1.9M	1.8M	1.6M
2018	3.0M	2.4M	2.3M	1.7M
2017	3.1M	3.2M	3.3M	3.4M
2016	1.2M	2.1M	0	3.0M
2015	4.4M	3.0M	1.7M	305.6K
2014	2.8M	2.5M	2.7M	4.7M
2013	0	0	0	3.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MyMD Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 24, 2023	rivard paul	bought	166,500	1.11	150,000	chief legal officer
Aug 17, 2023	rivard paul	bought	28,080	1.1232	25,000	chief legal officer
Dec 08, 2022	rivard paul	bought	15,300	1.53	10,000	evp of operations, gc
Nov 26, 2021	silverman joshua	bought	37,771	7.5543	5,000	-
Nov 24, 2021	silverman joshua	bought	65,586	6.55862	10,000	-
Nov 23, 2021	rivard paul	bought	90,450	6.03	15,000	evp of operations, gc
Apr 16, 2021	schroeder robert c	acquired	-	-	43,930	-
Apr 16, 2021	schroeder robert c	sold (taxes)	-72,588	4.94	-14,694	-
Apr 16, 2021	chapman christopher c jr	acquired	-	-	96,475	president, chief med. officer
Apr 16, 2021	silverman joshua	sold (taxes)	-189,326	4.94	-38,325	-

Which funds bought or sold MYMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-1,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-2,859	-	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-129	-	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	new	-	81.00	81.00	-%
Apr 24, 2024	BROWN ADVISORY INC	sold off	-100	-4,370	-	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	sold off	-100	-3,162	-	-%
Apr 19, 2024	Level Financial Advisors, Inc.	sold off	-100	-103	-	-%
Apr 19, 2024	ARVEST INVESTMENTS, INC.	sold off	-100	-258	-	-%
Apr 19, 2024	ARVEST INVESTMENTS, INC.	new	-	81.00	81.00	-%
Apr 18, 2024	SeaCrest Wealth Management, LLC	sold off	-100	-2,699	-	-%

Are Funds Buying or Selling MYMD?

Are funds buying MYMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MYMD

No. of Funds

Unveiling MyMD Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	iroquois capital management, llc	4.99%	187,421	SC 13G/A
Feb 14, 2024	global x management co llc	6.11%	3,108,473	SC 13G
Feb 14, 2023	iroquois capital management, llc	2.85%	31,184	SC 13G/A
Sep 08, 2022	duffey samuel s	5.86%	2,241,812	SC 13D
Feb 23, 2022	iroquois capital management, llc	3.66%	260,366	SC 13G/A
Feb 11, 2022	intracoastal capital, llc	1.0%	364,963	SC 13G/A

Recent SEC filings of MyMD Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	8-K	Current Report
Apr 08, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 26, 2024	8-K/A	Current Report
Mar 07, 2024	8-K	Current Report
Mar 05, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 13, 2024	8-K	Current Report

Peers (Alternatives to MyMD Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

MyMD Pharmaceuticals, Inc. News

Latest updates

MyMD Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2021Q1	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2
Revenue	-21.7%	43,453	55,497	67,541	79,585	420,812	464,513	612,123	279,405	557,089	526,601	302,475	938,771	675,831	1,072,861	1,034,069	995,278	956,486	738,023	-	170,016	340,031
Gross Profit	100.0%	-	-379,057	190,644	-267,390	135,302	244,649	366,186	-182,101	80,636	223,775	4,975	-594,518	352,304	782,270	408,529	283,694	679,638	537,995	263,134	-8,479	625,897
S&GA Expenses	122.3%	1,078,163	484,921	6,250	-69,446	6,163	14,139	149,841	448,053	364,641	469,469	500,152	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-29.5%	1,350,976	1,916,161	2,483,057	25,682	57,502	60,909	88,391	203,292	160,867	259,124	439,970	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	-Infinity%	-5.65	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-269,344	-	-
Earnings Before Taxes	-182.2%	-3,089,703	-1,094,909	-3,534,466	-763,396	-820,844	-794,891	-916,958	-3,837,640	-3,083,950	-2,067,453	-1,859,991	-	-	-	-	-	-	-	-	-	-
EBT Margin	-Infinity%	-6.54	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-182.2%	-3,089,704	-1,094,909	-981,949	-1,339,374	-837,026	-794,891	-916,958	-3,837,640	-3,083,950	-2,067,453	-1,859,991	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-Infinity%	-7.35	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-1,505,182	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-18.2%	17,862	21,826	25,249	28,409	17,540	20,231	19,161	22,204	24,813	28,010	34,448	35,798	29,761	23,725	18,678	9,122	10,885	4,971	5,932	7,042	7,807
Current Assets	-40.3%	5,816	9,736	13,143	16,287	5,402	8,077	6,992	10,072	12,665	15,948	22,375	34,298	150	23,566	18,478	8,296	10,311	4,315	5,250	5,962	6,670
Cash Equivalents	798.7%	2,681	298	94.00	189	749	310	1,115	1,189	556	1,375	2,127	569	148	16,190	11,447	812	517	363	248	276	182
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	193	199	412	544	601	585
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00	5.00	27.00	11.00	59.00	68.00	78.00	83.00
Goodwill	0%	10,499	10,499	10,499	10,499	10,499	10,499	10,499	10,499	10,499	10,499	10,499	-	-	-	-	-	-	-	-	-	-
Liabilities	-11.0%	5,089	5,716	13,747	14,402	2,845	1,904	3,043	2,581	1,166	2,118	3,374	2,374	5,934	2,556	2,706	2,304	1,530	1,373	1,618	2,076	1,974
Current Liabilities	-12.4%	4,988	5,696	2,429	1,626	2,769	1,781	2,903	2,467	1,040	2,092	3,348	2,374	2,348	2,556	2,706	2,180	1,530	1,373	-	-	1,974
Shareholder's Equity	-20.2%	12,370	15,501	10,742	13,094	14,695	18,327	16,118	19,622	23,647	25,892	31,074	33,424	34,579	21,169	15,972	6,817	9,355	3,598	4,314	4,966	5,834
Retained Earnings	-5.0%	-101,977	-97,085	-99,970	-95,428	-93,758	-90,013	-86,319	-82,683	-78,561	-75,321	-69,854	-138,646	-48,672	-133,876	-126,749	-123,121	-119,583	-118,243	-117,406	-116,611	-115,694
Shares Outstanding	28.9%	2,019	1,567	1,401	1,316	1,316	1,283	1,274	1,271	1,256	1,135	1,075	952	940	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	70,298	-	-	-	21,254	-	-	-	21,254	-	-	-	5,835	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	38.8%	-1,932	-3,156	-3,919	-3,971	-2,248	-15,955	8,300	-2,366	-4,812	-6,445	-6,753	-1,505	-1,248	-1,285	-163	-1,966	-501	-962	-861	-748	-2,638
Share Based Compensation	24.6%	742	596	1,677	-	162	352	132	-	-	15,036	15,036	980	567	273	6.00	1.00	3,552	-	-	-	-
Cashflow From Investing	76.6%	5,934	3,361	3,825	-11,274	2,688	-2,267	3,494	2,999	2,998	5,498	26,920	-15,565	-10,967	-21.33	-30.53	2,262	-6,309	1,077	470	823	-430
Cashflow From Financing	-Infinity%	-1,618	-	-	14,686	-	-	-	-	995	195	-2,910	1,794	1,349	1,275	2,053	77*	-	-	-	-	1,950

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MYMD Income Statement

2023-12-31

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses	5,442,886	5,520,150
Research and Development Expenses	7,867,795	9,067,422
Stock Based Compensation	3,049,537	695,191
Warrant Issuance Expenses	762,834
Loss from Operations	(17,123,052)	(15,282,763)
Other (Income) Expenses
Interest and Dividend Income	(455,570)	(83,991)
(Gain)/Loss on Sales of Marketable Securities	(416)	5,964
Unrealized (Gain)/Loss on Marketable Securities	(514)	(2,958)
Change in fair value of Derivatives Liabilities	(3,088,800)
Change in fair value of Warrant Liabilities	(9,756,000)
Uninsured Casualty Losses	178,198	(4,442)
Total Other (Income) Expenses	(13,123,102)	(85,427)
Loss Before Income Tax	(3,999,950)	(15,197,336)
Income Tax Benefit
Net Loss	(3,999,950)	(15,197,336)
Preferred Stock Dividends	4,218,213
Net Income/(Loss) Attributable to Common Stockholders	$ (8,218,163)	$ (15,197,336)
Net loss per common share - basic	$ (5.33)	$ (11.74)
Net loss per common share - diluted	$ (5.33)	$ (11.74)
Weighted average common shares outstanding - basic	1,542,453	1,294,200
Weighted average common shares outstanding - diluted	1,542,453	1,294,200

MYMD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and Cash Equivalents	$ 2,681,010	$ 749,090
Marketable Securities	2,242,106	4,086,902
Prepaid Expenses	893,226	565,787
Total Current Assets	5,816,342	5,401,779
Non-Current Assets
Operating Lease Right-of-Use Assets	47,389	139,662
Goodwill	10,498,539	10,498,539
Investment in Oravax, Inc.	1,500,000	1,500,000
Total Non-Current Assets	12,045,928	12,138,201
Total Assets	17,862,270	17,539,980
Current Liabilities
Trade and Other Payables	3,716,218	2,673,221
Operating Lease Liability	48,870	65,780
Derivative Liabilities	61,000
Warrant Liabilities	867,000
Dividends Payable	265,019
Total Current Liabilities	4,988,089	2,768,983
Non-Current Liabilities
Deferred Compensation Payable	100,538
Operating Lease Liability, net of current portion		75,941
Total Non-Current Liabilities	100,538	75,941
Total Liabilities	5,088,627	2,844,924
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Common stock, par value $0.001 per share, 16,666,666 shares authorized 2,018,857 and 1,315,674 issued and outstanding as of December 31, 2023 and December 31, 2022	2,019	1,316
Additional Paid In Capital	114,200,096	108,308,120
Accumulated Deficit	(101,977,067)	(93,758,904)
Total Stockholders’ Equity	12,369,572	14,695,056
Total Liabilities and Stockholders’ Equity	17,862,270	17,539,980
Series F Convertible Preferred Stock [Member]
Non-Current Liabilities
Series F Convertible Preferred Stock, with par value $0.001 per share and a stated value of $1,000 per share, 15,000 and 0 shares designated as of December 31, 2023 and December 31, 2022, 6,833 and 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022. Liquidation preference of $6,833,500 plus dividends at 10% per annum of $265,350 as of December 31, 2023.	404,071
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock value	144,524	144,524
Related Party [Member]
Current Liabilities
Due to MyMD Florida Shareholders	$ 29,982	$ 29,982

About MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

WEBSITE	mymd.com
INDUSTRY	Biotechnology
EMPLOYEES	9

MyMD Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for MyMD Pharmaceuticals, Inc.? What does MYMD stand for in stocks?

MYMD is the stock ticker symbol of MyMD Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MyMD Pharmaceuticals, Inc. (MYMD)?

As of Mon Apr 29 2024, market cap of MyMD Pharmaceuticals, Inc. is 6.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MYMD stock?

You can check MYMD's fair value in chart for subscribers.

What is the fair value of MYMD stock?

You can check MYMD's fair value in chart for subscribers. The fair value of MyMD Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MyMD Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MYMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MyMD Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether MYMD is over valued or under valued. Whether MyMD Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact MyMD Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MYMD.

What is MyMD Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, MYMD's PE ratio (Price to Earnings) is -1.56 and Price to Sales (PS) ratio is 3.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MYMD PE ratio will change depending on the future growth rate expectations of investors.